Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mardi, novembre 17
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
MapLight Therapeutics Inc
MPLT
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$6.90
-0.35
-4.83%
À la clôture: Nov 13, 4:00 PM EST
$7.00
-0.25
-3.45%
Pré-ouverture: 7:25 AM EST
Get Report
Aperçu
Actualités
Graphiques
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
MapLight Therapeutics Financials
MapLight Therapeutics (MPLT) financial statements — income, revenue, gross margin and key metrics.
Résultats:
Les résultats Q3 2026 ont été publiés le lun. nov. 16th, avant l'ouverture du marché
Earnings & Guidance News
PRO
MapLight Therapeutics Q3 EPS $(0.97) Beats $(1.16) Estimate
MapLight Therapeutics (NASDAQ:MPLT) reported quarterly losses of $(0.97) per share which beat the analyst consensus estimate of $(1.16) by 16.38 percent. This is a 97.39 percent increase over losses of $(37.18) per
Benzinga Newsdesk
PRO
MapLight Therapeutics Q2 EPS $(1.32) Beats $(1.35) Estimate
Benzinga Newsdesk
PRO
MapLight Therapeutics Q1 EPS $(1.34) Misses $(1.11) Estimate
MapLight Therapeutics (NASDAQ:MPLT) reported quarterly losses of $(1.34) per share which missed the analyst consensus estimate of $(1.11) by 20.72 percent. This is a 95.43 percent increase over losses of $(29.33) per
Benzinga Newsdesk
Earnings Scheduled For March 26, 2026
Benzinga Insights
PRO
MapLight Therapeutics Q4 EPS $(2.47) Misses $(0.96) Estimate
MapLight Therapeutics (NASDAQ:MPLT) reported quarterly losses of $(2.47) per share which missed the analyst consensus estimate of $(0.96) by 156.49 percent. This is a 91.16 percent increase over losses of $(27.95) per
Benzinga Newsdesk
PRO
MapLight Therapeutics Q3 EPS $(37.18) Misses $(1.55) Estimate
MapLight Therapeutics (NASDAQ:MPLT) reported quarterly losses of $(37.18) per share which missed the analyst consensus estimate of $(1.55) by 2291 percent. This is a 48.25 percent decrease over losses of $(25.08) per
Benzinga Newsdesk